Cited by 186Tuberculosis Research and EpidemiologyInfectious Diseases and TuberculosisDiagnosis and treatment of tuberculosis

Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in people living with HIV

Open access
Bjerrum, Stephanie, Schiller, Ian, Dendukuri, Nandini, Kohli, Mikashmi, Nathavitharana, Ruvandhi R, Zwerling, Alice A, Denkinger, Claudia M, Steingart, Karen R +1 more·2019·Cochrane Database of Systematic Reviews

Abstract

BACKGROUND: The lateral flow urine lipoarabinomannan (LF-LAM) assay Alere Determine™ TB LAM Ag is recommended by the World Health Organization (WHO) to help detect active tuberculosis in HIV-positive people with severe HIV disease. This review update asks the question, "does new evidence justify the use of LF-LAM in a broader group of people?", and is part of the WHO process for updating guidance on the use of LF-LAM. OBJECTIVES: To assess the accuracy of LF-LAM for the diagnosis of active tuberculosis among HIV-positive adults with signs and symptoms of tuberculosis (symptomatic participants) and among HIV-positive adults irrespective of signs and symptoms of tuberculosis (unselected participants not assessed for tuberculosis signs and symptoms).The proposed role for LF-LAM is as an add on to clinical judgement and with other tests to assist in diagnosing tuberculosis. SEARCH METHODS: We searched the Cochrane Infectious Diseases Group Specialized Register; MEDLINE, Embase, Science Citation Index, Web of Science, Latin American Caribbean Health Sciences Literature, Scopus, the WHO International Clinical Trials Registry Platform, the International Standard Randomized Controlled Trial Number Registry, and ProQuest, without language restriction to 11 May 2018. SELECTION CRITERIA: Randomized trials, cross-sectional, and observational cohort studies that evaluated LF-LAM for active tuberculosis (pulmonary and extrapulmonary) in HIV-positive adults. We included studies that used the manufacturer's recommended threshold for test positivity, either the updated reference card with four bands (grade 1 of 4) or the corresponding prior reference card grade with five bands (grade 2 of 5). The reference standard was culture or nucleic acid amplification test from any body site (microbiological). We considered a higher quality reference standard to be one in which two or more specimen types were evaluated for tuberculosis diagnosis and a lower quality reference standard to be one in which only one specimen type was evaluated. DATA COLLECTION AND ANALYSIS: Two review authors independently extracted data using a standardized form and REDCap electronic data capture tools. We appraised the quality of studies using the Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) tool and performed meta-analyses to estimate pooled sensitivity and specificity using a bivariate random-effects model and a Bayesian approach. We analyzed studies enrolling strictly symptomatic participants separately from those enrolling unselected participants. We investigated pre-defined sources of heterogeneity including the influence of CD4 count and clinical setting on the accuracy estimates. We assessed the certainty of the evidence using the GRADE approach. MAIN RESULTS: We included 15 unique studies (nine new studies and six studies from the original review that met the inclusion criteria): eight studies among symptomatic adults and seven studies among unselected adults. All studies were conducted in low- or middle-income countries. Risk of bias was high in the patient selection and reference standard domains, mainly because studies excluded participants unable to produce sputum and used a lower quality reference standard.Participants with tuberculosis symptomsLF-LAM pooled sensitivity (95% credible interval (CrI) ) was 42% (31% to 55%) (moderate-certainty evidence) and pooled specificity was 91% (85% to 95%) (very low-certainty evidence), (8 studies, 3449 participants, 37% with tuberculosis).For a population of 1000 people where 300 have microbiologically-confirmed tuberculosis, the utilization of LF-LAM would result in: 189 to be LF-LAM positive: of these, 63 (33%) would not have tuberculosis (false-positives); and 811 to be LF-LAM negative: of these, 174 (21%) would have tuberculosis (false-negatives).By clinical setting, pooled sensitivity was 52% (40% to 64%) among inpatients versus 29% (17% to 47%) among outpatients; and pooled specificity was 87% (78% to 93%) among inpatients versus 96% (91% to 99%) among outpatients. Stratified by CD4 cell count, pooled sensitivity increased, and specificity decreased with lower CD4 cell count.Unselected participants not assessed for signs and symptoms of tuberculosisLF-LAM pooled sensitivity was 35% (22% to 50%), (moderate-certainty evidence) and pooled specificity was 95% (89% to 96%), (low-certainty evidence), (7 studies, 3365 participants, 13% with tuberculosis).For a population of 1000 people where 100 have microbiologically-confirmed tuberculosis, the utilization of LF-LAM would result in: 80 to be LF-LAM positive: of these, 45 (56%) would not have tuberculosis (false-positives); and 920 to be LF-LAM negative: of these, 65 (7%) would have tuberculosis (false-negatives).By clinical setting, pooled sensitivity was 62% (41% to 83%) among inpatients versus 31% (18% to 47%) among outpatients; pooled specificity was 84% (48% to 96%) among inpatients versus 95% (87% to 99%) among outpatients. Stratif

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/14651858.cd011420.pub3

Cites

139 of 140 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 141 references couldn’t be matched to a known paper.

Research works printed but not linked: 21

  1. Bisson GP, Gupta A, Miyahara S, Sung X, Bao J, Fry CL, et al. Urine LAM testing in advanced HIV‐infected adults in a trial of empiric TB therapy. Topics in Antiviral Medicine. 2016; Vol. 24, issue E‐1: 312‐ 13.
  2. Blanc FX, Badje AD, Bonnet M, Gabillard D, Messou E, Muzoora C, et al. Systematic vs test‐guided tuberculosis treatment: Data of the statis randomized trial. Topics in Antiviral Medicine. 2018; Vol. 26, issue Supplement 1: 13s‐ 14s.
  3. Drain P, Grobler A, Gounder L, Sahid F, Wilson D, Bassett I, et al. Rapid urine lipoarabinomannan testing after two months of tuberculosis treatment independently predicts mortality in a resource‐limited setting. 44th World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease. Paris, 2013; Vol. 17 (Suppl 2): S264.
  4. Elsawy A, Redwan EM. Urine lipoarabinomannan as initial markers for active pulmonary tuberculosis. Australian Journal of Basic and Applied Sciences 2012; 6(3): 751‐ 5.
  5. Grant A, Charalambous S, Tlali M, Johnson S, Dorman S, Hoffmann C, et al. Empirical TB treatment in advanced HIV disease: Results of the TB fast track trial. Topics in Antiviral Medicine. 2016; Vol. 24, issue E‐1: 61‐ 62.
  6. Gupta‐Wright A, Corbett EL, Oosterhout JJ Van, Wilson DK, Grint, D, Alufandika‐Moyo M, et al. Urine‐based screening for tuberculosis: A randomized trial in HIV‐positive inpatients. Topics in Antiviral Medicine. 2018; Vol. 26, issue Supplement 1: 18s‐ 19s.
  7. Koulchin VA, Boehme C, Molokova E, Turecheck C, Hoelscher M, Perkins M, et al. Evaluation of the detection of urinary lipoarabinomannan as a tool for diagnosis of mycobacterial infections. Abstracts of the General Meeting of the American Society for Microbiology 2007; 107: 174‐ 5.
  8. Lawn SD, Kerkhoff A, Burton R, Schutz C, Wyk G van, Vogt M, et al. Massive diagnostic yield of HIV‐associated tuberculosis using rapid urine assays in South Africa. Conference on Retroviruses and Opportunistic Infections (CROI). Boston (MA), 2014.
  9. Leopold B, Samuel N, Aimable D, Joannes C. New diagnostic tests for tuberculosis: Performance of LAM and Xpert MTB/RIF in urine of hospitalized patients on intensive phase of TB treatment, and its association with TB dissemination and HIV status. Preliminary results from an observational cohort study in Kigali, Rwanda. Tropical Medicine and International Health. 2017; Vol. 22, issue Supplement 1: 35. [DOI: http://dx.doi.org/10.1111/%28ISSN%291365‐3156] · DOI
  10. Mathabire SC, Cossa L, Mpunga J, Manhica I, Quiles IA, Molfino L, et al. Feasibility of using Determine‐TB LAM test in HIV‐infected adults in programmatic conditions. Journal of the International Aids Society. 2017; Vol. 20: 18.
  11. Reddy KP, Gupta‐Wright A, Fielding K, Costantini S, Zheng A, Corbett EL, et al. Cost‐effectiveness of urine TB screening for hospitalized people with HIV in Africa. Topics in Antiviral Medicine. 2018; Vol. 26, issue Supplement 1: 518s.
  12. Tlali M, Fielding K, Charalambous S, Karat A, Hoffmann C, Johnson S, et al. Sensitivity of the TB Determine LAM test compared to sputum culture gold standard TB in ambulant HIV positive participants enrolled in the TB fast track study in South Africa. 4th South African TB Conference. Durban, 2014.
  13. Rie A Van, Jong E, Mkhwanazi M, Sanne I. Diagnosing TB in those hardest to diagnose: urine lipoarabinomannan for suspects of disseminated and extrapulmonary TB. Conference on Retroviruses and Opportunistic Infections (CROI). Atlanta (GA), 2013: 443.
  14. Veritas Health Innovation. Covidence systematic review software. Available at www.covidence.org. Melbourne: Veritas Health Innovation, 2017.
  15. Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
  16. TB CARE I. International Standards for Tuberculosis Care, Edition 3. TB Care 1, The Hague. who.int/tb/publications/ISTC_3rdEd.pdf?ua=1 (accessed 16 Nov 2014): 1‐ 87.
  17. D Boyle. Tuberculosis Diagnostics Technology and Market Landscape. 5th Edition. Vernier: World Health Organization Unitaid Secretariat, 2017.
  18. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. 2nd Edition. Geneva: World Health Organization, 2016. 27466667
  19. World Health Organization. Guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy. Geneva: World Health Organization, 2017. 29341560
  20. World Health Organization. The use of Loop‐mediated Isothermal Amplification (TB‐LAMP) for the diagnosis of pulmonary tuberculosis: Policy guidance. Geneva: World Health Organization, 2016. 27606385
  21. World Health Organization. Automated real‐time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF system for the diagnosis of pulmonary and extrapulmonary TB in adults and children: policy update. WHO/HTM/TB/2013.16. Geneva: World Health Organization, 2013. 25473701

Cited by

Sorted by citations

Authors
Bjerrum, S., Schiller, I., Dendukuri, N., Kohli, M., Nathavitharana, R. R., Zwerling, A. A., Denkinger, C. M., Steingart, K. R., & Shah, M.
Affiliations
  • University of Southern Denmark (DK)
  • McGill University Health Centre (CA)
  • McGill University (CA)
  • Beth Israel Deaconess Medical Center (US)
  • University of Ottawa (CA)
  • FIND (CH)
  • Liverpool School of Tropical Medicine (GB)
  • Johns Hopkins University (US)
Corresponding author
Bjerrum, Stephanie
Venue
Cochrane Database of Systematic Reviews
Publisher
Wiley
Published
2019-10-21
Volume
2019
Issue
10
Pages
CD011420-CD011420
ISSN
  • 1361-6137 (ISSN-L)
  • 1465-1858
OpenAlex
W2982248582
Cited by
186
References
141
Citations by year
2026: 15 · 2025: 31 · 2024: 29 · 2023: 22 · 2022: 35 · 2021: 28 · 2020: 24 · 2019: 2
FWCI
3.12
Type
journal article
Language
en
Open access
Licence
cc-by-nc-sa
Locations
  • Cochrane Database of Systematic Reviews (publishedVersion, cc-by-nc-sa)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • LSTM Online Archive (Liverpool School of Tropical Medicine) (acceptedVersion)
  • University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion, cc-by-nc-sa)
Funders
National Institute of Allergy and Infectious Diseases (K23AI132648)
Topics
  • Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
  • Health Sciences › Medicine › Surgery › Infectious Diseases and Tuberculosis
  • Health Sciences › Medicine › Surgery › Diagnosis and treatment of tuberculosis
Keywords
lipoarabinomannan, lateral flow assay, active tuberculosis, HIV, tuberculosis diagnosis, diagnostic accuracy, sensitivity and specificity, extrapulmonary tuberculosis, CD4 count

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review